Today: 22 May 2026
McCormick stock tumbles as MKC flags tariff costs and a softer 2026 profit outlook
22 January 2026
2 mins read

McCormick stock tumbles as MKC flags tariff costs and a softer 2026 profit outlook

New York, January 22, 2026, 15:03 ET — Regular session

  • McCormick shares dropped roughly 8% following Q4 results and a 2026 profit forecast that missed expectations
  • Company cites tariffs, commodity costs, and investment spending as pressures on margins
  • Investors wrestle with robust sales growth forecasts amid a narrow earnings outlook

Shares of McCormick & Co dropped 7.9% to $61.27 in Thursday’s afternoon session, following the company’s warning about rising tariff and commodity expenses. The spice maker also issued a 2026 profit forecast that came in under Wall Street’s estimates.

This move is significant since McCormick, a key player in staples with heavy exposure to pantry goods, is still grappling with cost pressures from trade policies and raw materials, with no sign of relief. CEO Brendan Foley told analysts, “Approximately 50% of the incremental tariffs on McCormick items remain in place,” estimating the tariff impact at around $50 million for fiscal 2026. Deutsche Bank’s Steve Powers warned the stock might face near-term pressure despite solid sales trends. Reuters

Investors face a familiar dilemma, now with a twist: solid top-line growth, yet rising costs. If tariffs persist or grow, spices and herbs offer few straightforward alternatives.

McCormick reported adjusted earnings per share of 86 cents for the fourth quarter, excluding certain one-time items to improve comparability, on net sales around $1.85 billion. The company projected fiscal 2026 adjusted EPS between $3.05 and $3.13, with net sales expected to rise 13% to 17%. It also noted that “global trade dynamics continue to create headwinds.” SEC

Here’s the tension in the outlook: the company forecasts sales growth outpacing earnings growth. That dynamic tends to shift focus onto pricing power and how quickly cost savings roll in, rather than just the top-line revenue figure.

Management highlighted several factors driving the margin squeeze: rising commodity prices, tariffs, and increased spending on capacity and brand marketing. The company reported a decline in gross margin compared to the prior year, framing the change in “basis points”—a term meaning one-hundredth of a percentage point—commonly used to measure small shifts in margins.

During the quarter, McCormick’s consumer segment saw modest volume growth alongside price hikes, whereas its flavor solutions unit experienced smaller gains and some volume weakness. Investors are watching that divide closely as a test of whether pricing can outpace costs without hurting demand.

The broader market showed little volatility. The S&P 500 tracker SPY gained roughly 0.6%, while the consumer staples ETF XLP hovered near flat. That left McCormick standing out as a notable laggard. Meanwhile, packaged-food rivals Kraft Heinz, General Mills, and Conagra all pushed higher.

McCormick revealed board updates this week, naming Rick Dierker from Church & Dwight and ex-Molson Coors CEO Gavin Hattersley as directors starting Feb. 1. “We are delighted to welcome Gavin and Rick to McCormick’s Board,” Foley said in the statement. SEC

However, the stock is driven by margins, not governance. The risk is clear-cut: tariffs drag on past management’s forecast, commodity prices stay elevated, or consumers resist price increases more than anticipated, leaving McCormick to shoulder more inflation pressure.

Investors will now watch for signs that pricing moves and productivity efforts can quickly counter the tariff impact to shore up margins. A separate filing reveals the company’s annual meeting is set for April 1, 2026, where two directors are expected to step down.

Stock Market Today

  • Q1 Earnings Review: Azenta Falls; West Pharmaceutical Leads Drug Development Services Stocks
    May 21, 2026, 9:31 PM EDT. Drug development inputs and services stocks, essential for pharmaceutical research and manufacturing, reported mixed Q1 results. Azenta (NASDAQ:AZTA), specializing in biological sample management, posted disappointing results with $144.8 million revenue, missing estimates and the weakest among peers, causing its share price to drop 23.4% to $17.65. Conversely, West Pharmaceutical Services (NYSE:WST), maker of specialized packaging and delivery devices, delivered a strong quarter with $844.9 million revenue, beating estimates by 8.4%. Overall, the sector's revenues beat consensus by 1.6%, despite an average 2.5% share price decline post-earnings. Tailwinds include growth in biologics and gene therapies, while headwinds feature pricing pressure and regulatory risks.

Latest articles

OpenAI Shares Hype Returns, Still No Ticker in Sight

OpenAI Shares Hype Returns, Still No Ticker in Sight

22 May 2026
OpenAI is preparing to confidentially file for a U.S. IPO, aiming to go public as early as September, sources told Reuters. The move follows a court win against Elon Musk, removing a key legal obstacle. Private-market share prices for OpenAI ranged from $658.94 to $732.38 this month, but no official public price exists. Ordinary investors still cannot buy OpenAI stock on public exchanges.
Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

22 May 2026
Estée Lauder and Spain’s Puig ended merger talks that would have created a $40 billion beauty group. Estée Lauder shares rose about 10% in after-hours trading, closing the regular session at $78.91. The company said it will focus on its turnaround plan and continue reviewing possible acquisitions or divestitures.
WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

22 May 2026
WhiteFiber shares jumped 22.2% to $29.55 after announcing a five-year AI compute contract worth over $160 million for a Paris-region deployment using NVIDIA GPU systems. Google Finance showed the stock rising further after hours. The project is backed by planned financing and 12 months of customer prepayments, but funding and execution remain pending. Service is expected to start in July, subject to equipment delivery and acceptance.
Nebius (NBIS) stock swings as Israel AI supercomputer launch hits tape, investors eye contract deadlines
Previous Story

Nebius (NBIS) stock swings as Israel AI supercomputer launch hits tape, investors eye contract deadlines

Abbott stock sinks 10% after outlook misses estimates — what ABT investors watch next
Next Story

Abbott stock sinks 10% after outlook misses estimates — what ABT investors watch next

Go toTop